Teclistamab
Genmab,Janssen
['teclistamab']
 #asco23 63% response rates achieved in triple class refractory #myeloma patients with off-the-shelf #teclistamab! accelerated approval was granted, with confirmatory results to come. #meded #oncology #clinicaltrial 
COR2ED bringing you Independent Medical Education developed 
by LYMPHOMA & MYELOMA CONNECT, international experts in hematology and oncology